Søren Tulstrup will be stepping down from his position by mutual agreement as CEO after seven years of dedicated service to the company.

“With the appointment of Renée as CEO, Hansa is entering a new phase of growth and development. Renée brings extensive experience in both the biopharmaceutical and financial sectors, and her proven leadership will be instrumental in advancing the company’s strategic positioning. The Board is confident that she is the right person to successfully lead Hansa through this next chapter,” says Peter Nicklin, Chairman of the Board, Hansa Biopharma. 

Renée Aguiar-Lucander

Aguiar-Lucander served for seven years as CEO of Calliditas Therapeutics where she led the company through a dual listing on NASDAQ in both Sweden and the U.S. During her tenure, the company launched and commercialized the first ever approved drug for immunoglobulin A (IgA) nephropathy in the U.S. and until it was acquired by Asahi Kasei Corporation of Japan in September 2024. Prior to that, Aguiar-Lucander had a long and career in the healthcare investment sector, holding senior roles in funds such as Omega Funds and 3i Group.

Related article

Asahi Kasei to acquire Calliditas Therapeutics

Asahi Kasei Corp has announced that it will offer the shareholders of Calliditas Therapeutics to acquire the shares of the pharmaceutical company Calliditas for the purpose of making Calliditas a wholly-owned subsidiary of Asahi Kasei through a voluntary tender offer for Calliditas. In the Board’s opinion, the combination of Asahi Kasei and Calliditas will leverage […]


“I am delighted and honored to take up the position of CEO of Hansa during this exciting and challenging times. I hope to bring relevant perspectives from my previous roles, both with regards to capital raising and management, as well as insights regarding regulatory, commercial preparation and launch dynamics,” says Aguiar-Lucander.

Related article

Q&A: Renée Aguiar-Lucander, CEO, Calliditas Therapeutics

Calliditas Therapeutics is about to bring its treatment for IgA nephropathy to the market – addressing a significant unmet medical need. Calliditas, formed in 2004, is a Swedish clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases. The company’s lead product […]